Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been given an average rating of “Moderate Buy” by the eight brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $66.6667.

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. D. Boral Capital lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, Maxim Group lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter worth about $58,000. XTX Topco Ltd raised its position in Reviva Pharmaceuticals by 63.6% in the 4th quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock worth $46,000 after buying an additional 63,893 shares during the last quarter. Lido Advisors LLC purchased a new position in Reviva Pharmaceuticals in the 3rd quarter worth about $37,000. Finally, Millennium Management LLC raised its position in Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after buying an additional 223,178 shares during the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

Shares of Reviva Pharmaceuticals stock opened at $0.41 on Tuesday. The firm has a market capitalization of $5.41 million, a P/E ratio of -0.10 and a beta of 0.75. The business has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $5.39. Reviva Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $23.20.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Analysts predict that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.